0001209191-23-037183.txt : 20230614 0001209191-23-037183.hdr.sgml : 20230614 20230614185815 ACCESSION NUMBER: 0001209191-23-037183 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230612 FILED AS OF DATE: 20230614 DATE AS OF CHANGE: 20230614 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ildstad Suzanne CENTRAL INDEX KEY: 0001845822 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40384 FILM NUMBER: 231015565 MAIL ADDRESS: STREET 1: C/O TALARIS THERAPEUTICS, INC. STREET 2: 93 WORCESTER STREET, SUITE 120 CITY: WELLESLEY STATE: MA ZIP: 02481 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Talaris Therapeutics, Inc. CENTRAL INDEX KEY: 0001827506 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 570 PRESTON ST. STREET 2: SUITE 400 CITY: LOUISVILLE STATE: KY ZIP: 40202 BUSINESS PHONE: 502-398-9250 MAIL ADDRESS: STREET 1: 93 WORCESTER STREET CITY: WELLESLEY STATE: MA ZIP: 02481 4 1 doc4.xml FORM 4 SUBMISSION X0407 4 2023-06-12 0 0001827506 Talaris Therapeutics, Inc. TALS 0001845822 Ildstad Suzanne C/O TALARIS THERAPEUTICS, INC. 570 S. PRESTON ST. LOUISVILLE KY 40202 1 0 0 0 1 Common Stock 2023-06-12 4 S 0 16870 2.5919 D 3798542 D Common Stock 2023-06-13 4 S 0 14208 2.5576 D 3784334 D Common Stock 2023-06-14 4 S 0 12942 2.4914 D 3771392 D Common Stock 654205 I See footnote Common Stock 654205 I See footnote Stock Option (Right to Buy) 2.54 2023-06-13 4 A 0 20500 0.00 A 2033-06-13 Common Stock 20500 20500 D The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.52 to $2.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.52 to $2.56, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.43 to $2.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. These shares are held in a trust for the benefit of the Reporting Person's son. The Reporting Person's son is co-trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. These shares are held in a trust for the benefit of the Reporting Person's daughter. The Reporting Person's daughter is co-trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. The shares underlying this option shall vest as follows: the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting. /s/ Mary Kay Fenton, attorney-in-fact 2023-06-14